Breaking News Instant updates and real-time market news.

JD

JD.com

$33.57

0.21 (0.63%)

, WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include JD.com (JD), consensus 17c... Wave Life Sciences (WVE), consensus ($1.44)... Rhythm Pharmaceuticals (RYTM), consensus (88c)... JCPenney (JCP), consensus (56c).

JD

JD.com

$33.57

0.21 (0.63%)

WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

RYTM

Rhythm Pharmaceuticals

$21.52

0.38 (1.80%)

JCP

J.C. Penney

$1.10

0.01 (0.92%)

  • 15

    Nov

  • 15

    Nov

  • 09

    Dec

JD JD.com
$33.57

0.21 (0.63%)

10/22/19
VERF
10/22/19
INITIATION
VERF
Buy
JD.com initiated with a Buy at Vertical Group
Vertical Group analyst a a initiated coverage of JD.com with a Buy citing strong Q3 growth and brand demand.
10/11/19
EGHT
10/11/19
UPGRADE
EGHT
Buy
JD.com upgraded to Buy from Hold at 86 Research
86 Research upgraded JD.com to Buy from Hold, stating that its September investor conference gave it better visibility into JD's expected margin expansion. The firm also sees the stock having reached an attractive entry point following the recent pullback in shares. 86 raised its price target on JD.com shares to $41 from $35.
08/19/19
LEHM
08/19/19
INITIATION
Target $36
LEHM
Equal Weight
JD.com initiated with an Equal Weight at Barclays
Barclays analyst Gregory Zhao initiated JD.com with an Equal Weight rating and $36 price target, stating that while its recently accelerated revenue growth and margin expansion outlook "are very impressive," he also thinks the turnaround is largely priced into the stock. He is also concerned that JD may miss some significant opportunities, such as in Cloud and payment, as it focuses on retail.
08/19/19
LEHM
08/19/19
INITIATION
Target $32
LEHM
Overweight
Pinduoduo initiated with an Overweight at Barclays
Barclays analyst Gregory Zhao initiated Pinduoduo (PDD) with an Overweight rating and $32 price target, noting that the company has been able to break through the Alibaba (BABA) and JD.com (JD) duopoly to accumulate a sizeable user base with its unique team-buy, social marketplace model. He expects upside in its ARPU and take rate during its expansion into the high-end market, Zhao noted.
WVE Wave Life Sciences
$27.90

-0.07 (-0.25%)

11/01/19
11/01/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Digi International (DGII) initiated with an Outperform at Baird. 2. Wave Life Sciences (WVE) initiated with a Buy at Guggenheim. 3. PPG (PPG) resumed with an Equal Weight at Morgan Stanley. 4. Homology Medicines (FIXX) initiated with a Perform at Oppenheimer. 5. Sarepta (SRPT) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/19
GUGG
11/01/19
INITIATION
Target $43
GUGG
Buy
Wave Life Sciences initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijam initiated coverage of Wave Life Sciences with a Buy rating and $43 price target.
07/01/19
MZHO
07/01/19
NO CHANGE
Target $65
MZHO
Buy
Mizuho incrementally more positive on Wave Life Sciences after update
Mizuho analyst Salim Syed is incrementally more positive on Wave Life Sciences after the company provided an enrollment update on suvodirsen's open-label expansion. Interim dystrophin expression is still expected to come in the second half of 2019 and remains a key catalyst for Wave, Syed tells investors in a research note. The analyst points out that there have been no treatment discontinuations so far in the open-label expansion. Syed keeps a Buy rating on Wave Life Sciences with a $65 price target.
05/20/19
RHCO
05/20/19
NO CHANGE
Target $39
RHCO
Buy
Wave Life Sciences price target lowered to $39 from $60 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Wave Life Sciences to $39 to reflect its "turbulent" April. The analyst cites the company's top-line data from the ongoing Phase I/II PRECISION-HD program being pushed back to 2019-end from first-half end and its suvodirsen study in Duchenne Muscular Dystrophy raising concerns about its safety and tolerability. Longer term, Nash keeps his Buy rating on Wave Life Sciences however, saying he continues to see value in its platform technology and forecasting the upcoming data from its DMD and HD programs in the second half of the year to "mark turning points for the stock."
RYTM Rhythm Pharmaceuticals
$21.52

0.38 (1.80%)

07/12/19
STFL
07/12/19
UPGRADE
Target $34
STFL
Buy
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
Stifel analyst Derek Archila upgraded Rhythm Pharmaceuticals to Buy from Hold with an unchanged price target of $34. The analyst sees an attractive entry point into the shares given setmelanotide's positive Phase 2 data, which he says demonstrated a meaningful benefit on weight loss and hunger scores. Both Phase 3 studies, expected in Q3, will likely be positive and a "homerun" scenario could move the stock to the low $40 range, Archila tells investors in a research note.
03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target
Ladenburg Thalmann analyst Michael Higgins initiated coverage of Rhythm Pharmaceuticals with a Buy rating and $43 price target. Rhythm is developing setmelanotide, a novel weight-loss drug for ultra-orphan genetic obesity disorders caused by mutations in the melanocortin-4 receptor signaling pathway, Higgins tells investors in a research note. The analyst urges investors to accumulate a position ahead of upcoming 2019 milestones, particularly pro-opiomelanocortin and leptin receptor deficiency pivotal data in Q3. Target $43.
03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Rhythm Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Rhythm Pharmaceuticals with a Buy rating and $43 price target.
JCP J.C. Penney
$1.10

0.01 (0.92%)

07/25/19
OPCO
07/25/19
NO CHANGE
Target $390
OPCO
Outperform
Ulta Beauty price target raised to $390 from $370 at Oppenheimer
Oppenheimer analyst Rupesh Parikh raised his price target for Ulta Beauty (ULTA) to $390 from $370 given the company's meaningful overlap with J.C. Penney (JCP) stores that have a Sephora inside and following media reports saying that the latter has hired advisors to explore debt restructuring options. While the company subsequently confirmed that it has not hired advisors for an in-court restructuring or bankruptcy, the analyst points out that he views Ulta Beauty as a potential beneficiary of any store rationalization down the road at J.C. Penney. Parikh says Ulta remains a top pick, and reiterates an Outperform rating on the shares.
01/16/19
FBCO
01/16/19
NO CHANGE
Target $50
FBCO
Neutral
Nordstrom price target lowered to $50 from $55 at Credit Suisse
Credit Suisse analyst Michael Binetti lowered his price target for Nordstrom (JWN) to $50 from $55 on weak full-price holiday adding to already clearance filled January. With Nordstrom adding to industry markdown issues, the analyst sees negative reads for J.C. Penney (JCP), Kohl's (KSS), Gap (GPS), but positive for Burlington Stores (BURL), Ross Stores (ROST), and TJX (TJX). Binetti reiterates a Neutral rating on Nordstrom shares.
01/09/19
FBCO
01/09/19
NO CHANGE
FBCO
J.C. Penney looks best positioned to gain share from Sears, says Credit Suisse
Looking at potential near-term same-store sales lift Softlines Retail peers could see from share gains based on proximity to Sears (SHLD) stores amid a possible liquidation, Credit Suisse analyst Michael Binetti says J.C. Penney (JCP) and Burlington Stores (BURL) seem best positioned to gain share in 2019 due to close proximity. And while J.C. Penney looks best positioned to gain share from Sears, the analyst thinks the recent stock run-up is "a short-term bounce." Binetti does not see this as sustainable customer acquisition for J.C. Penney given the increased risk of closing destabilized malls, limited visibility to an improved merchandise strategy, and leverage constraints to growth investing. Overall, the analyst believes that while there may be some near-term share benefit, a Sears liquidation could be a bigger tipping point that will accelerate closures of already weakening U.S. C&D malls.
11/16/18
11/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Home Depot (HD) downgraded to Neutral from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying peak growth has passed. 2. J.C. Penney (JCP) downgraded to Sell from Hold at Argus with analyst John Eade saying he anticipates continued losses for the stock for the next two years while also warning that at a current share price below $2, the company is operating with a more elevated risk. 3. Nvidia (NVDA) was downgraded to Neutral from Buy at B. Riley FBR and to Buy from Conviction Buy at Goldman Sachs. 4. Michael Kors (KORS) downgraded to Perform from Outperform at Oppenheimer with analyst Brian Nagel saying he is "concerned" that ongoing challenges with inventory management and replenishment at the company's namesake brand and softness within fashion watches will weigh on top-line trends and potentially margins, just as management begins the integration of Versace. 5. TSMC (TSM) was downgraded to Equal Weight from Overweight at Morgan Stanley while UMC (UMC) was downgraded to Underweight from Equal Weight. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

DDRLF

Maersk Drilling

$0.00

(0.00%)

06:42
12/11/19
12/11
06:42
12/11/19
06:42
Initiation
Maersk Drilling initiated  »

Maersk Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVMK

SurveyMonkey

$17.09

-0.25 (-1.44%)

06:40
12/11/19
12/11
06:40
12/11/19
06:40
Conference/Events
SurveyMonkey management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SAPMY

Saipem

$0.00

(0.00%)

06:39
12/11/19
12/11
06:39
12/11/19
06:39
Downgrade
Saipem rating change  »

Saipem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUBCY

Subsea 7

$0.00

(0.00%)

06:38
12/11/19
12/11
06:38
12/11/19
06:38
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$20.09

-1.17 (-5.50%)

06:37
12/11/19
12/11
06:37
12/11/19
06:37
Conference/Events
Canopy Growth management to meet with Cantor Fitzgerald »

Cantor Analyst Pablo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TFX

Teleflex

$353.75

-3.65 (-1.02%)

06:35
12/11/19
12/11
06:35
12/11/19
06:35
Conference/Events
Teleflex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ACM

Aecom

$42.69

0.32 (0.76%)

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Recommendations
Aecom analyst commentary  »

Citi continues to like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$57.61

0.49 (0.86%)

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Conference/Events
Seagate management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 07

    Jan

ACM

Aecom

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Recommendations
Aecom analyst commentary  »

Citi continues to like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONO

Sonos

$13.50

-0.12 (-0.88%)

06:32
12/11/19
12/11
06:32
12/11/19
06:32
Conference/Events
Sonos management to meet with DA Davidson »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

AIT

Applied Industrial Technologies

$63.84

-0.35 (-0.55%)

06:31
12/11/19
12/11
06:31
12/11/19
06:31
Recommendations
Applied Industrial Technologies analyst commentary  »

Applied Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$191.74

-4.15 (-2.12%)

06:31
12/11/19
12/11
06:31
12/11/19
06:31
Recommendations
Cigna analyst commentary  »

Cigna potential unit sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

URI

United Rentals

$153.77

-2.2 (-1.41%)

06:27
12/11/19
12/11
06:27
12/11/19
06:27
Recommendations
United Rentals analyst commentary  »

United Rentals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRCX

Lam Research

$269.10

2.19 (0.82%)

, MKSI

MKS Instruments

$106.68

1.45 (1.38%)

06:26
12/11/19
12/11
06:26
12/11/19
06:26
Recommendations
Lam Research, MKS Instruments analyst commentary  »

Citi remains long…

LRCX

Lam Research

$269.10

2.19 (0.82%)

MKSI

MKS Instruments

$106.68

1.45 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AEE

Ameren

$74.58

0.6 (0.81%)

06:22
12/11/19
12/11
06:22
12/11/19
06:22
Initiation
Ameren initiated  »

JPMorgan starts Ameren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,739.15

-10.46 (-0.60%)

06:21
12/11/19
12/11
06:21
12/11/19
06:21
Hot Stocks
U.K. CMA says Amazon's Deliveroo investment raises competition concerns »

Earlier this year, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.82

9.35 (2.75%)

06:19
12/11/19
12/11
06:19
12/11/19
06:19
Recommendations
Tesla analyst commentary  »

Baird sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$12.33

1.28 (11.58%)

06:19
12/11/19
12/11
06:19
12/11/19
06:19
Recommendations
Citi boosts PG&E target to $10.50, says no chance of zero stock price now »

Citi analyst Praful Mehta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

TSLA

Tesla

$348.82

9.35 (2.75%)

06:16
12/11/19
12/11
06:16
12/11/19
06:16
Periodicals
Tesla to raise prices of imported Model 3s in China, Reuters reports »

Tesla plans to raise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

OLLI

Ollie's Bargain Outlet

$60.28

(0.00%)

06:14
12/11/19
12/11
06:14
12/11/19
06:14
Recommendations
Ollie's Bargain Outlet analyst commentary  »

Ollie's Bargain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.82

9.35 (2.75%)

06:14
12/11/19
12/11
06:14
12/11/19
06:14
Periodicals
Tesla plans to build 500,000 vehicles per year at German factory, Reuters says »

Tesla plans to produce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PBPB

Potbelly

$4.50

0.08 (1.81%)

06:12
12/11/19
12/11
06:12
12/11/19
06:12
Downgrade
Potbelly rating change  »

Potbelly downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.86

-3.39 (-0.97%)

06:11
12/11/19
12/11
06:11
12/11/19
06:11
Periodicals
FAA chief Dickson to testify before Congress on Boeing 737 MAX, Reuters reports »

FAA chief Steve Dickson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$35.58

-0.57 (-1.58%)

06:10
12/11/19
12/11
06:10
12/11/19
06:10
Syndicate
Constellation Pharmaceuticals 6.5M share Spot Secondary priced at $34.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

RCKT

Rocket Pharmaceuticals

$24.22

1.22 (5.30%)

06:08
12/11/19
12/11
06:08
12/11/19
06:08
Syndicate
Rocket Pharmaceuticals 3.82M share Spot Secondary priced at $22.25 »

JPMorgan, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.